Loading...
Based on the data provided, Quipt Home Medical Corp (QIPT) is not a strong buy for a beginner, long-term investor at this moment. While the stock has a bullish moving average trend and a take-private transaction at $3.65 per share, the overbought RSI, lack of recent news catalysts, and declining net income and EPS suggest caution. The investor may consider holding off for now and reassessing later.
The stock shows bullish moving averages (SMA_5 > SMA_20 > SMA_200), but the RSI of 82.187 indicates an overbought condition. The MACD histogram is negative (-0.00714) and contracting, suggesting weakening momentum. Key resistance is at $3.619 and $3.634, while support levels are at $3.569 and $3.554.

Gross margin improved by 6.10% YoY to 56.38%. Additionally, there is a take-private transaction at $3.65 per share, which is slightly above the current pre-market price of $3.62.
The stock is overbought based on RSI, and the MACD indicates weakening momentum. There is no significant hedge fund or insider trading activity, and no recent news or congress trading data is available.
In Q1 2026, revenue increased by 31.96% YoY to $80.996M, but net income dropped by -2.86% YoY to -$1.05M. EPS fell by -33.33% YoY to -0.02, while gross margin improved by 6.10% YoY to 56.38%.
Canaccord analyst Richard Close raised the price target to $3.65 from $2.30 and maintained a Hold rating. The update reflects the company's Q4 FY'25 results and the take-private transaction at $3.65 per share.